Entero Therapeutics, Inc. (ENTO) Dividend History

Entero Therapeutics, Inc. (ENTO) is a biopharmaceutical company focused on developing neuromodulation therapies for gastrointestinal and metabolic diseases. The company leverages its proprietary EnteroMedics platform, including the vagus nerve modulation technology, to develop treatments aimed at improving conditions such as obesity and other gastrointestinal disorders.

777 Yamato Road, Boca Raton, FL, 33431
Phone: 561-589-7020
Website: https://www.enterothera.com

Dividend History

Entero Therapeutics, Inc. currently does not pay dividends

Company News

Entero Therapeutics Appoints Richard Paolone as CEO

Entero Therapeutics, a clinical-stage biopharmaceutical company, has appointed Richard Paolone as the interim CEO. Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions.

GlobeNewswire Inc.
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of SUM, ENTO, ALVR and STAF

The M&A Class Action Firm is investigating the proposed mergers of Summit Materials, Entero Therapeutics, AlloVir, and Staffing 360 Solutions, providing details on the terms of each merger and encouraging shareholders to contact the firm for more information.

GlobeNewswire Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM, LBRDA, ENTO, LLYVA on Behalf of Shareholders

Halper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed mergers and transactions involving Pulmatrix, Liberty Broadband, Entero Therapeutics, and Liberty Media.

GlobeNewswire Inc.

Featured Companies: FWONA
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero Therapeutics, Inc. – ENTO

Monteverde & Associates PC, a class action law firm, is investigating the proposed merger between Entero Therapeutics, Inc. (ENTO) and Journey Therapeutics, Inc., where Journey Therapeutics shareholders will acquire 99% of Entero's equity.

GlobeNewswire Inc.
Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Entero Therapeutics and Journey Therapeutics announce a proposed reverse merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Journey's next-gen, first-in-class nano-immunoconjugates platform and Entero's gastrointestinal product pipeline.

GlobeNewswire Inc.

Dividend data last updated 06/08/2025 01:47:21 UTC